Agios Pharmaceuticals Inc header image

Agios Pharmaceuticals Inc

AGIO

Equity

ISIN null / Valor 21630028

NASDAQ (2025-11-20)
USD 24.57+9.98%

Agios Pharmaceuticals Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Agios Pharmaceuticals Inc is a biopharmaceutical company that specializes in the discovery and development of novel therapies for rare diseases, with a particular emphasis on hemolytic anemias. Leveraging its expertise in cellular metabolism, Agios has made significant strides in the field, marked by the FDA approval of its first rare disease therapy for adults with pyruvate kinase (PK) deficiency. The company's pipeline includes mitapivat, its lead product candidate currently undergoing late-stage clinical trials for thalassemia and sickle cell disease. Additionally, Agios is working on AG-946, a new PK activator aimed at treating hemolytic anemias among other conditions. Beyond these leading programs, Agios is actively engaged in preclinical development, working on advancing a range of investigational therapies that promise to further its mission of addressing unmet medical needs in rare disease communities.

Summarized from source with an LLMView SourceSector: Technology

Latest Results (11.10.2025):

Agios Pharmaceuticals Inc reported its financial results for the second quarter of 2025, showcasing significant growth in net revenues and progress in its clinical pipeline. The company continues to strengthen its financial position with substantial cash reserves, supporting ongoing and future initiatives.

Revenue Growth

Net product revenue from PYRUKYND® (mitapivat) reached $12.5 million in Q2 2025, up from $8.6 million in Q2 2024, driven by a 6% increase in unique patient enrollments and a 4% rise in patients on therapy.

Regulatory Progress

The supplemental New Drug Application (sNDA) for PYRUKYND® in thalassemia is under active FDA review with a PDUFA goal date of September 7, 2025. Additionally, topline results from the RISE UP Phase 3 trial in sickle cell disease are on track for year-end, with a potential U.S. commercial launch in 2026.

R&D Advancements

Agios dosed the first patient in the Phase 2 tebapivat trial for sickle cell disease and received IND clearance for AG-236, targeting polycythemia vera. The company also continues to expand its clinical pipeline with ongoing trials in lower-risk myelodysplastic syndromes (LR-MDS).

Financial Position

As of June 30, 2025, Agios held $1.3 billion in cash, cash equivalents, and marketable securities. Despite increased research and development and selling, general and administrative expenses, the company expects its financial resources to support product launches and pipeline advancement.

Summarized from source with an LLMView Source

Key figures

-55.0%1Y
-12.9%3Y
-43.6%5Y

Performance

55.6%1Y
49.2%3Y
53.7%5Y

Volatility

Market cap

1428 M

Market cap (USD)

Daily traded volume (Shares)

7,666,286

Daily traded volume (Shares)

1 day high/low

33.39 / 32.32

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Rational AG
Rational AG Rational AG Valor: 635626
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.24%EUR 618.00
Nemetschek SE
Nemetschek SE Nemetschek SE Valor: 329782
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.74%EUR 89.00
Bechtle Aktiengesellschaft
Bechtle Aktiengesellschaft Bechtle Aktiengesellschaft Valor: 1060508
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.52%EUR 38.38
QXO Inc
QXO Inc QXO Inc Valor: 135786409
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.23%USD 16.10
TeamViewer SE
TeamViewer SE TeamViewer SE Valor: 50049146
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.96%EUR 5.50
CompuGroup Medical SE & Co. KGaA
CompuGroup Medical SE & Co. KGaA CompuGroup Medical SE & Co. KGaA Valor: 55499718
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.02%EUR 24.20
Procore Technologies Inc
Procore Technologies Inc Procore Technologies Inc Valor: 53026320
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.14%USD 69.49
SoftwareOne Holding Ltd.
SoftwareOne Holding Ltd. SoftwareOne Holding Ltd. Valor: 49645150
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.91%CHF 8.28
Lem Holding SA
Lem Holding SA Lem Holding SA Valor: 2242762
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.00%CHF 303.50
Landis+Gyr Group Ltd
Landis+Gyr Group Ltd Landis+Gyr Group Ltd Valor: 37115349
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%CHF 51.60